Nasus Pharma Ltd. NSRX
2.91 USD -0.07 (-2.51%)
Nov 11, 2026, 3:59 PM EST
2.89 Day range 3.02
2.01 52-week range 9.15
- YTD
- -68.20%
- 1 year
- -61.20%
News
globenewswire.com Nasus Pharma Announces Abstracts Accepted for Presentation at ACAAI 2026 TEL AVIV, Israel, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative…
benzinga.com This Kazia Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday Analysts initiated coverage with Buy/Overweight ratings on KZIA ($27), PSQL ($12), NSRX ($7) and LGCY ($16).
benzinga.com Maxim Group Initiates Coverage On Nasus Pharma with Buy Rating, Announces Price Target of $7 Maxim Group analyst Naz Rahman initiates coverage on Nasus Pharma (AMEX:NSRX) with a Buy rating and announces Price Target of $7.
globenewswire.com Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron Topline Data from First-in-Human Pharmacokinetic Study Anticipated in the Fourth Quarter of 2026 Topline Data from First-in-Human Pharmacokinetic Study Anticipated in the Fourth Quarter of 2026
globenewswire.com Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis Clinical study to evaluate NS002, the Company's investigational intranasal epinephrine powder, as a needle-free alternative to EpiPen® for patients experiencing anaphylaxis and will compare…
globenewswire.com Nasus Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference TEL AVIV, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the development of…
globenewswire.com Nasus Pharma Announces Transition of Chief Financial Officer TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE American: NSRX) ("Nasus", “Nasus Pharma” or the "Company"), a clinical-stage pharmaceutical company focused on the…
benzinga.com Nasus Pharma H1 EPS $(0.54) Misses $(0.20) Estimate Nasus Pharma (AMEX:NSRX) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.20) by 170 percent. This is a 217.65 percent decrease over losses of $(0.17)…
globenewswire.com Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update Appointed Pharma Industry Veteran Brendan O'Grady as Chief Executive Officer Company on Track to Advance Clinical Programs to Key Second Half 2026 Milestones TEL AVIV, Israel, Aug. 17, 2026 (GLOBE…
defenseworld.net Nasus Pharma (NYSEAMERICAN:NSRX) Trading Up 9.7% – Here’s Why Nasus Pharma Ltd. (NYSEAMERICAN:NSRX - Get Free Report)'s share price was up 9.7% during mid-day trading on Tuesday. The stock traded as high as $3.60 and last traded at $3.50. Approximately 70,095…
benzinga.com Nasus Pharma Appoints Brendan O'Grady As CEO, Succeeding Dan Teleman, Effective July 27 Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced the
globenewswire.com Nasus Pharma Appoints Pharmaceutical Industry Veteran Brendan P. O'Grady as Chief Executive Officer to Lead Strategic Growth TEL AVIV, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus", "Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of…
globenewswire.com Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum TEL AVIV, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative…
benzinga.com Nasus Pharma Announces NS003 Trial Demonstrates Preclinical Pharmacokinetic Profile Comparable To IV Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced positive results…
globenewswire.com Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003) Study Comparing Intranasal Powder Formulation of Ondansetron Demonstrates Comparable Pharmacokinetic Profile to Intravenous Ondansetron in Animal Study; Program to Advance to First-in-Human PK Study…
globenewswire.com Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative…
globenewswire.com Nasus Pharma to Participate in Upcoming Investor Conferences TEL AVIV, Israel, May 01, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
benzinga.com Citizens Maintains Market Outperform on Nasus Pharma, Lowers Price Target to $18 Citizens analyst Jason N. Butler maintains Nasus Pharma (AMEX:NSRX) with a Market Outperform and lowers the price target from $19 to $18.
benzinga.com Nasus Pharma Announces Phase 2 Results From NS002 Shows Improvements In Early Absorption Compared To EpiPen; Pivotal Trial Planned For !4 Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced the filing of…
globenewswire.com Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update Recent Phase 2 topline results demonstrate NS002's potential for best-in-class epinephrine delivery, with statistically significant improvements in early absorption compared to EpiPen®; pivotal study…
globenewswire.com BriefCast Publishes Transcript: Nasus Pharma NS002 Phase 2 Positive Topline Results Webinar Transcript In a call hosted recently, Nasus Pharma (NYSE:NSRX) presented strong positive topline results from its Phase 2 clinical study evaluating NS002, its investigational intranasal epinephrine powder for…- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com What's Going On With Nasus Pharma Stock On Wednesday The Phase 2 study results indicated that NS002 has the potential to exceed EpiPen performance, demonstrating statistically significant improvements in the time to therapeutic threshold.
benzinga.com What's Going On With Nasus Pharma Stock On Wednesday Nasus Pharma stock drops despite fast NS002 results beating EpiPen. Here's why shares are falling and what the data shows.- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Nasus Pharma Stock Hits 52-Week Low - Here's Why Nasus Pharma (NSRX) hits a 52-week low despite positive Phase 2 data for its EpiPen rival. See why the stock is down 43% today.
benzinga.com Crude Oil Down 4%; Dollar Tree Earnings Top Views 
benzinga.com Dow Jumps Over 500 Points; NY Empire State Manufacturing Index Falls In March US stocks rise, Nasdaq gains 100 pts. Dow up 1.14%, Nasdaq up 1.38%, S&P 500 up 1.24%. Financial shares up 1.6%, energy stocks up 0.2%. NY Empire State Manufacturing Index declines to -0.2 in March.- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Nasus Pharma's Topline Results From Phase 2 Study Of NS002 For Anaphylaxis Shows NS002 Achieved Significantly Faster And Higher Early Epinephrine Absorption Compared To Intramuscular Epipen Autoinjector NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T100 of 1.69 minutes versus 3.42 minutes (p=0.033). At 5 minutes, 88.4%…
globenewswire.com Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T100 of 1.69 minutes versus 3.42 minutes (p=0.033). At 5 minutes, 88.4%…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Nasus Pharma To Present Topline Analysis From Its Phase 2 Repeated Dose Clinical Study Of NS002 Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that members of…
globenewswire.com Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study TEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative…
globenewswire.com Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum TEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative…- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com Nasus Pharma Announces Interim Results From Phase 2 Clinical Study Of NS002, Investigational Intranasal Epinephrine Powder Formulation For Treatment Of Anaphylaxis Interim results indicate NS002 demonstrated significantly faster absorption and higher peak epinephrine levels compared to EpiPen®91% of study participants achieved the 100 pg/ml plasma threshold at…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session - benzinga.com Citizens Initiates Coverage On Nasus Pharma with Market Outperform Rating, Announces Price Target of $19 Citizens analyst Jason Butler initiates coverage on Nasus Pharma (AMEX:NSRX) with a Market Outperform rating and announces Price Target of $19.
- benzinga.com Nasus Pharma Appoints Eyal Rubin As EVP And CFO Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma", "Nasus" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency…
- benzinga.com Nasus Pharma Initiates Phase 2 Clinical Study To Evaluate NS002 Investigational Intranasal Epinephrine Powder Formulation With Dosing Of First Patient To Treat Anaphylaxis Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical…
- benzinga.com Nasus Pharma Announces Health Canada Has Issued A No-Objection Letter Allowing The Company To Proceed With A Phase 2 Clinical Trial Of NS002, Its Intranasal Epinephrine Powder Being Developed For The Treatment Of Anaphylaxis Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Laidlaw & Co. Initiates Coverage On Nasus Pharma with Buy Rating, Announces Price Target of $22 Laidlaw & Co. analyst Yale Jen initiates coverage on Nasus Pharma (AMEX:NSRX) with a Buy rating and announces Price Target of $22.
- benzinga.com Nasus Pharma Prices $10M Initial Public Offering Of 1.25M Ordinary Shares At $8.00 Per Share The Company intends to use the net proceeds from the initial public offering for furthering the development of its intranasal Epinephrine program, including, manufacturing scale-up and additional…